Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn’s Disease? A Meta-analysis of Controlled Clinical Trials

BACKGROUND: Tumor necrosis factor-α (TNF-α) antibodies are currently used in patients with moderate to severe Crohn’s disease (CD) who are unresponsive to conventional therapies. Certolizumab pegol (Cp) is one of the anti-TNF-α agents introduced for the management of CD and rheumatoid arthritis. OBJ...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Nikfar, Shekoufeh, Ehteshami-Afshar, Solmaz, Abdollahi, Mohammad
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Kowsar 2013
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3918190/
https://ncbi.nlm.nih.gov/pubmed/24578833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5812/ircmj.11258
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller